Empagliflozin as add-on to metformin in people with Type 2 diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Empagliflozin as add-on to metformin in people with Type 2 diabetes

Published:2015-07-14 Issue:12 Volume:32 Page:1555-1567
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:Diabet. Med.

Author:

Merker L.¹,Häring H-U.²,Christiansen A. V.³,Roux F.⁴,Salsali A.⁵,Kim G.⁶,Meinicke T.⁷,Woerle H. J.⁶,Broedl U. C.⁶,

Affiliation:

1. Diabetes- und Nierenzentrum; Dormagen Germany

2. University of Tübingen; Tübingen Germany

3. Boehringer Ingelheim Danmark A/S; Copenhagen Denmark

4. Boehringer Ingelheim France S.A.S.; Reims France

5. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield CT USA

6. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim Germany

7. Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach Germany

Funder

Boehringer Ingelheim

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dme.12814/fullpdf

Reference24 articles.

1. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors;Grempler;Diabetes Obes Metab,2012

2. SGLT2 inhibitors in the treatment of type 2 diabetes;Hasan;Diabetes Res Clin Pract,2014

3. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes;Heise;Diabetes Obes Metab,2013

4. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial;Roden;Lancet Diabetes Endocrinol,2013

5. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial;Barnett;Lancet Diabetes Endocrinol,2014

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

2. Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial;Beni-Suef University Journal of Basic and Applied Sciences;2023-11-08

3. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2023-08-28

4. How SGLT2 inhibitors interact with metformin? A molecular dynamics study;Molecular Simulation;2023-04-01

5. Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post-Authorisation Safety Study;International Journal of Clinical Medicine;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3